Some important considerations for validation of ligand-binding assays

Area of Science:

• Pharmacokinetics
• Analytical Chemistry
• Biotechnology

Background:

• Ligand-binding assays (LBAs) are crucial for quantifying analytes in biological samples.
• Macromolecule LBAs present unique challenges compared to small molecule assays, including complex reference standards and potential interferences.
• Non-linear calibration curves in LBAs necessitate careful selection of curve-fitting algorithms.

Purpose of the Study:

• To highlight the complexities and limitations of calibrating and validating ligand-binding assays (LBAs) for macromolecules.
• To emphasize the need for cautious interpretation of LBA-derived data, particularly pharmacokinetic parameters for proteins.
• To advocate for rigorous validation approaches in LBA development and implementation.

Main Methods:

• Discussion of challenges in LBA calibration curve fitting for non-linear data.
• Comparison of validation strategies for small molecule versus macromolecule LBAs.
• Exploration of potential interferences in macromolecule LBAs from degradation products.
• Consideration of total error and confidence intervals for LBA validation.

Main Results:

• Macromolecule reference standards are more complex than those for small molecules.
• Cross-validation with chromatography is more straightforward for small molecule LBAs than for macromolecule LBAs.
• Unknown interferences from biotransformation products can compromise the accuracy of macromolecule LBA results.
• Pharmacokinetic data derived from macromolecule LBAs should be viewed with caution.

Conclusions:

• The accuracy of macromolecule concentrations and pharmacokinetic data determined by LBAs requires careful consideration due to potential interferences.
• Rigorous validation methods, including total error and confidence interval assessments, are essential for the reliable implementation of LBAs.
• Further research into understanding and mitigating interferences in macromolecule LBAs is warranted.